Mongolia EMS Funding: 103, Ulaanbaatar Emergency Care, EMD and Regional Procurement

Research snapshot · 14 August 2026. Mongolia is not a one-tariff ambulance market. The defensible financing and procurement hierarchy is national healthcare framework → Ulaanbaatar or aimag/public provider → specific ambulance organization.

Emergency line 103 and Ulaanbaatar

The Communications Regulatory Commission identifies 103 as the national ambulance number. Emergency calls are connected free of charge through domestic telecommunications networks. In Ulaanbaatar, the Niisleliin Türgen Tuslamjiin Töv (Capital City Emergency Medical Center) operates a 24/7 prehospital ambulance service with several local bases across the city.

Insurance and financing

Mongolia’s Health Insurance General Authority lists Ulaanbaatar Emergency Medical Center as a contracting healthcare provider for Ambulance / Emergency Medical Assistance. This makes insurance-backed and public provider financing more relevant to an EMS technology than a generic patient tariff. A single current public ground-ambulance fee for the entire country could not be independently verified.

Procurement level

For AIRCHILL, Ulaanbaatar represents the most identifiable first purchaser market. Outside the capital, aimag-level public healthcare structures and individual hospitals or ambulance providers are the relevant units. The Ministry of Health sets national standards and programmes; vehicle and device budgets can be deployed institutionally and locally.

AIRCHILL market-access approach

Start with Ulaanbaatar, the largest urban system with an identifiable public operator.
Expand aimag by aimag rather than creating an artificial national tariff.
Do not assume a separate routine reimbursement code for a new respiratory cooling device.
Focus on procurement and evidence-generating pilots rather than the patient transport fee.

Primary sources

Data boundary: The national emergency number is not a single nationwide ambulance patient price. Provider/aimag fees and contracts are entered only if backed by current official publications.

English working translation of the German original. Source figures retain their original 2026 research-snapshot dates. The publication does not establish any AIRCHILL-specific reimbursement or device authorization. Market-data source review pending.